XML 37 R23.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Schedule II | 12 Months Ended
--- | ---
Oct. 31, 2015
Valuation and Qualifying Accounts [Abstract] |
Schedule II | Schedule II THE COOPER COMPANIES, INC. AND SUBSIDIARIES VALUATION AND QUALIFYING ACCOUNTS Three Years Ended October 31, 2015
(In millions) | Balance Beginning of Year |  | Additions Charged to Costs and Expenses |  | (Deductions) Recoveries/ Other (1) |  | Balance at End of Year
Allowance for doubtful accounts: |  |  |  |  |  |  |
Year Ended October 31, 2015 | $ | 6.0 |  |  | $ | 1.7 |  |  | $ | (1.7 | ) |  | $ | 6.0 |
Year Ended October 31, 2014 | $ | 5.3 |  |  | $ | 1.7 |  |  | $ | (1.0 | ) |  | $ | 6.0 |
Year Ended October 31, 2013 | $ | 4.4 |  |  | $ | 1.5 |  |  | $ | (0.6 | ) |  | $ | 5.3 |
(1) Consists of additions representing allowances and recoveries, less deductions representing receivables written off as uncollectible.
(In millions) | Balance Beginning of Year |  | Additions (2) |  | Reductions/ Charges (3) |  | Balance at End of Year
Income tax valuation allowance: |  |  |  |  |  |  |
Year Ended October 31, 2015 | $ | 14.5 |  |  | $ | — |  |  | $ | (1.1 | ) |  | $ | 13.4 |
Year Ended October 31, 2014 | $ | 1.0 |  |  | $ | 13.5 |  |  | $ | — |  |  | $ | 14.5 |
Year Ended October 31, 2013 | $ | 1.1 |  |  | $ | — |  |  | $ | (0.1 | ) |  | $ | 1.0 |
(2) During the fiscal fourth quarter of 2014, we recorded in purchase accounting deferred tax assets in connection with its acquisition of Sauflon Pharmaceuticals, Ltd., and subsidiaries. A valuation allowance of $13.5 million was set up against Sauflon Hungary's development tax credits. (3) During the fiscal third quarter of 2013, we revalued deferred tax assets and liabilities residing in Denmark, along with the related valuation allowance to reflect the newly enacted tax rate change that incrementally decreased the corporate tax rate.

X
- Definition The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 09 -Article 12 + Details
Name: | us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ValuationAndQualifyingAccountsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration